Top Markets
#1 MowCat MowCat +48.45%
#2 Bermuda Shorts Bermuda Shorts +31.49%
#3 Biconomy Biconomy +22.77%
#4 Velvet Velvet +21.04%
#5 Derive Derive +17.92%
#6 MarsCoin MarsCoin +17.75%
#7 Quack AI Quack AI +17.33%
#8 Audiera Audiera +14.23%
#9 Perle Perle +14.15%
#10 aPriori aPriori +13.82%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
Rangering i aksjer #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Aksjekurs
$0.594
Sist synkronisert: 2026-08-14
Markedsverdi
$4.50M
Endring (1 dag)
0.00%
Endring (1 år)
-66.44%
Land
US
Handel Mustang Bio, Inc. (MBIO)

Kategori

Healthcare
Inntekter for Mustang Bio, Inc. (MBIO)
Inntekter i 2026 TTM: 0
Ifølge Mustang Bio, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Mustang Bio, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE